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Pseudomonas aeruginosa infections are increasingly problematic due to their multiple 
antibiotic resistances. To date, there is no commercial vaccine against P. aeruginosa 
infection. This study used polyhydroxyalkanoate (PHA) beads as a delivery platform 
for selected P. aeruginosa antigens to produce novel particulate vaccines against P. 
aeruginosa. Genetic engineering was used to modify the PHA synthase (PhaC), the 
enzyme that catalyses PHA bead formation, to produce functionalised PHA beads 
displaying the antigens. The highly conserved PopB antigen, recently revealed as an 
effective stimulator of Th17 immunity was displayed on the bead surface together 
with and without the previously selected antigens Ag (epitopes derived from outer 
membrane proteins OprI, OprF and AlgE). The PHA beads were produced in two 
production strains: (1) the pathogen P. aeruginosa itself, with the benefit of co-
purifying host cell proteins (HCPs) expanding the antigen repertoire that could boost 
the immune response, and (2) E. coli strain ClearColiTM, a defined mutant incapable 
of lipopolysaccharide synthesis enabling production of endotoxin free PHA beads. 
Vaccination of mice with antigen-coated PHA beads (only PopB or with additional 
Ag) showed increased production of IL-17, a reflection of induction of a Th17 
immunity. Furthermore, Th1 and Th2 mediated immunity were detected from the IgG 
analysis of the immunised mice with the PHA bead vaccines. Significant enhancement 
of Th1 immune response using the PHA bead platform was observed compared to the 
antigen-only counterparts. Challenge of immunised mice with pathogenic P. 
aeruginosa showed that PopB-displaying PHA beads from P. aeruginosa and Ag-
displaying PHA beads from E. coli induced partially protective immunity. The 
promising PHA bead candidate vaccines can be conjugated with other antigens such 
as the exopolysaccharide Psl for induction of improved immune response towards 
protective immunity.  
 
Exopolysaccharide Psl is a mannose rich polymer produced by P. aeruginosa in both 
mucoid and nonmucoid phenotypes. Psl has been revealed to play an essential role in 
P. aeruginosa pathogenicity such as biofilm formation. Previous studies had provided 
evidence that CdrA binds directly to Psl, functioning as a Psl cross-linker and possibly 
tethering Psl to the cell surface. Psl is commercially not available, hence the aim of 
this study was to develop a Psl production strain. This study created a cdrA knockout 
mutant that produces free Psl which may be a potential vaccine antigen against P. 
ii 
 
aeruginosa infections. An isogenic knockout of cdrA was obtained by homologous 
recombination and this mutant overproduced Psl released from the cell surface. In 
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